pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
910
stories
19d
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
19d
Biotech leaders call for streamlining of INDs as FDA’s Trialblazer rolls out
biospace
19d
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
22d
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
22d
UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma
biospace
22d
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer
endpoints
22d
Opinion: Limb girdle muscular dystrophy patients face a maddening reality
stat
22d
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
biospace
22d
Replimune melanoma drug wins support of FDA panel
biopharma dive
23d
Capricor’s data clash and a fugitive in the C-suite
stat
23d
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
fiercebiotech
23d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
23d
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
23d
Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
biospace
23d
Life after the lead asset: Advancing an early-stage pipeline
biospace
23d
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
fiercebiotech
23d
STAT+: FDA expert committee votes in favor of Replimune’s melanoma treatment
stat
23d
Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
fiercebiotech
23d
Chronically ill people face confusion over new Medicaid work rules and ‘medically frail’ exemption
stat
23d
Labcorp posts higher Q2 earnings on strength of diagnostics, lab services; adjusts full-year guidance
fiercebiotech
23d
New funding, new jobs: 4 biotechs hiring after series B raises
biospace
23d
J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech
endpoints
23d
Researchers concerned by underutilization of accelerated approval in oncology
raps
24d
STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
stat
24d
NYU's Neil Vasan departs as acting chair of FDA's cancer drug advisory panel
endpoints
24d
Caldera, Vidya add to recent flurry of biotech mergers
biopharma dive
24d
Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
biopharma dive
24d
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
biopharma dive
24d
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
24d
STAT+: Pharmalittle: We’re reading about a fugitive who became a biotech exec, a hospital suing Lilly, and more
stat
← prev
page 8 of 31
next →
